2019年10月13日(日) 14:50 〜 16:30 第14会場 (パレスルームA)

Chair: Yoshio TSUBOI (Department of Neurology, Fukuoka University, Japan), Discussant: ‌Masato ASANUMA (Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan)

Parkinson’s disease (PD) is a syndrome rather than a disease. Indeed, based on the clustering analysis using artificial intelligence (AI), clinical phenotypes could be classified for three groups such as mild motor predominant, intermediate, and diffuse malignant forms. In addition, there are at least 23 loci or monogenic forms of familial PD. Thus, PD is highly heterogeneous. Based on the information from functions of causative genes, mitochondrial dysfunctions, lysosomal dysfunctions, neuroinflammation, and prion like propagation have been also proposed as pathomechanisms. However, more information has not translated into greater understanding of disease complexity to satisfy diagnostic and therapeutic needs. Challenges include the need for wide-scale and long-term deployment of sensor technology, and the gap between the “big data” acquired with sensitive measurement technologies and their limited clinical application. Major opportunities could be realized if new technologies are developed as part of open-source and/or open-hardware platforms enabling multi-channel data capture, sensitive to the broad range of motor and non-motor problems that characterize PD, and adaptable into self-adjusting, individualized treatment delivery systems. We would lie to propose the patient’s based managements for PD as precision medicine. This symposium is consisting of four speakers who will be talking about motor and non-motor symptoms for pharmacological treatments, respectively. In addition, this includes non-pharmacological treatment for PD such as DBS and precision medicine based on genetic studies.